150 results about "N gonorrhoeae" patented technology

The present invention relates to nanosilver-containing antibacterial and antifungal granules ("NAGs"). The NAGs have longlasting inhibitory effect on a broad-spectrum of bacteria and fungi, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C. The NAGs contain ground stalk marrow of the plant Juncus effusus L. which has been dispersed with nanosilver particles. The nanosilver particles are about 1-100 nm in diameter. Each of the nanosilver particles contain a metallic silver core which is surrounded by silver oxide. The present invention also provides a process for making the NAGs. The NAGs can be used in a variety of healthcare and industrial products. Examples of the healthcare products include, but are not limited to, ointments or lotions to treat skin trauma, soaking solutions or cleansing solutions for dental or women hygiene, medications for treating gastrointestinal bacteria infections, sexual related diseases, and eye diseases. Examples of industrial products include, but are not limited to, food preservatives, water disinfectants, paper disinfectants, construction filling materials (to prevent mold formation).

The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.

A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

The invention relates to a fluorescence PCR (polymerase chain reaction) detection method for diagnosing infection of Chlamydia trachomatis (CT), neisseria gonorrhoeae (NG) and ureaplasma urealyticum (UU), which belongs to the field of nucleic acid in vitro diagnosis. The method comprises a polymerase chain reaction (PCR) system based on fluorescence PCR technology, contains a forward primer and areverse primer aiming at the CT/the NG/the UU and a fluorescent probe, and can detects DNA of three pathogens such as the CT, the NG, the UU and the like simultaneously in a reaction tub under suitable PCR condition. The method can diagnosing the infection of the CT/the NG/the UU in a clinical sample simply, conveniently and rapidly, has high sensitivity and specificity, and has important clinical value to early control and prevention of relevant genitourinary tract infections, blocking of an infection sources, and infection reduction of related pathogen.

This invention provides compositions and methods for detecting Neisseria gonorrhoeae in a sample. This invention also provides related reaction mixtures, kits, systems, and computers.

A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and mast cell degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-Ile-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

Present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or therapeutic reagent.

The invention provides pubes-cleaning disinfection nursing liquid used for the pudendum and the vagina of a human body, which consists of 'chlorhexidine acetate (or chlorhexidine gluconate), borneol and osthole' added with a proper amount of synergist and the balance of distilled water, wherein the pH value is adjusted to be 4 to 5 by a pH balance factor. The product can kill pathogenic bacteria of HIV, neisseria gonorrhoeae, staphylococcus aureus, escherichia coli, candida albicans and the like and other viruses in one minutes so as to block cross infections of various infectious diseases, eliminate smells and relieve itching.

The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics. Relying on this personalized diagnostic tool, physicians can better inform about antibiotic susceptibility and thereby open up medical intervention avenues for treating Neisseria gonorrhoeae with antibiotics. There is provided a therapeutic application of the antibiotic resistance profile that has advantages of: (i) providing a more effective regime for gonorrhea treatment; and (ii) halting the evolutionary pressures towards antibiotic resistance in the Neisseria gonorrhoeae therapy.

The present invention relates to primers and probes that can be used in various assays to detect a new strain of Chlamydia trachomatis. The invention further provides for the simultaneous detection of other diseases, especially Neisseria gonorrhoeae.

The invention relates to a real-time PCR (polymerase chain reaction) method for quintuply detecting target nucleic acid in a nucleic acid extracting solution in a single PCR reaction vessel, which is used for detecting Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in a sample.

Disclosed are a DNA chip and a kit capable of quickly and accurately detecting or genotyping the highly prevalent and important eleven microbes causing sexually transmitted diseases (STD) Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, Mycoplasma hominis, syphilis-causing treponema, pallidum, chancroid-causing Haemophilus ducreyi, genital herpes-causing herpes simplex virus 1 and 2, human papillomavirus (HPV) and Trichomonas vaginalis and three related organisms Candida albicans, Gardnerella vaginalis and coliform bacteria and analyzing antibiotic resistance against tetracycline and lactam antibiotics, and a method for detecting or genotyping using the same. According to the present invention, the presence, genotype and antibiotic resistance of the fourteen organisms can be analyzed quickly and accurately from a DNA sample. With excellent sensitivity, specificity, reproducibility and accuracy of the 14 STD-causing and related microorganisms may be automatically identified quickly and accurately from multiple samples, and selection of antibiotics may be aided.

The invention relates to the detection of three different bacterial species which are responsible for sexually-transmitted diseases, i.e., Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG). The invention more particularly relates to the detection of these three species in real-time PCR, in multiplex PCR and in real-time multiplex PCR. The invention provides reference templates sequences, which are especially adapted to the design of primers and probes, which can be used together in the same tube to detect CT and/or MG and/or NG by real-time multiplex amplification.

Compositions and methods for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number. Described herein is a method that entails assaying a sample obtained from the urogenital tract of the mammal for an indicator of genomic copy number, wherein a genomic copy number level that is higher than a control genomic copy number level is indicative of the presence of infection or inflammation of the urogenital tract. Also described in a kit of the invention that includes a primer and/or probe for detecting or sequencing an indicator of genomic copy number, wherein the indicator of genomic copy number comprises a nucleic acid sequence that is expected to be present in the genome of the mammal in one or two copies; and a primer and/or probe for detecting or sequencing a nucleic acid sequence that is indicative of a pathogen that infects the urogenital tract or a miRNA correlated with inflammation.

The invention discloses a nano-silver cleaning sterilizing shower gel which is prepared by the following materials according to weight percentage: 15 percent to 25 percent of surfactant (AES), 8 percent to 12 percent of mild surfactant, 8 percent to 12 percent of amphoteric surfactant, 0.001 percent to 0.01 percent of nano-silver, 0.1 percent to 0.3 percent of chelating agent, 0.1 percent to 0.2 percent of citric acid (Acd), 0.2 percent to 1 percent of flavor, 50 percent to 70 percent of distilled water, 0.1 percent to 0.2 percent of preservative and 1 percent to 3 percent of thickener. The preparation method is as follows: the nano-silver particles are dissolved in the distilled water and uniformly mixed with the chelating agent after floating particles are filtrated; then the mixture is heated to the constant temperature of 80 DEG C and the surfactant is added into the mixture and uniformly mixed; after the mild surfactant is added into the mixture and uniformly mixed, the amphoteric surfactant is added into the mixture and the mixture is cooled to 45 DEG C; the citric acid is added into the mixture and uniformly mixed, and the pH value is adjusted to be between 5.5 and 7.0; during the cooling, the flavor, the preservative, the thickener and pigments are added in sequence and blended while being added until the temperature drops to the room temperature. The shower gel has strong bactericidal function to chlamydia trachomatis and the neisseria gonorrhoeae of sexually transmitted diseases.

The invention discloses a gonococcus, chlamydia trachomatis and ureaplasma urealyticum detection kit. The detection kit comprises a gene chip (1) and various primers (2), wherein the gene chip carries (i) nucleotide probes of different pathogens, (ii) a biotin point-labeled DNA (deoxyribonucleic acid) sequence and (iii) a DNA sequence carrying beta-globulin encoding part; the nucleotide probes are a sequence of SEQ ID Nos:1-3 or a sequence complementary to SEQ ID Nos:1-3; the biotin point-labeled DNA sequence is SEQ ID No.4; the DNA sequence carrying beta-globulin encoding part serving as an internal control point is SEQ ID No.5; and various primers are used for amplifying the DNA sequences in a clinical sample, and have DNA sequences of SEQ ID Nos.6-11. The kit can quickly and accuratelydetect infections of gonococcus, chlamydia trachomatis and ureaplasma urealyticum, and has magnificent meaning to pathogen detection.

The invention provides a method for detecting mutation of drug-resistant sites of 19 neisseria gonorrhoeae. The method utilizes a multiplex PCR-mass spectrometry method to detect the mutation of the drug-resistant sites of the 19 neisseria gonorrhoeae. The detection method comprises the following steps: 1) designing primers for different drug-resistant sites; 2) carrying out multiplex PCR amplification reaction; 3) treating shrimp alkaline phosphatase; 4) carrying out single base extension reaction; 5) desalting and purifying resin; and 6) carrying out mass spectrometric detection.

The present invention relates to immunogenic compositions comprising a recombinant Neisseria gonorrhoeae OpcA and methods of eliciting an immune response in a mammal by administering a formulation comprising N. gonorrhoeae OpcA or a portion or fragment of N. gonorrhoeae OpcA. The invention also provides for methods and kits for diagnosing N. gonorrhoeae infection using said recombinant N. gonorrhoeae OpcA.

WO99/24578 discloses a large number of proteins from Neisseria meningitidis and Neisseria gonorrhoeae. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed.